Skip to main content
OpenTrials
Recruiting

NCT Number: NCT02356497

Prospective Evaluation of Interventional Studies on Bone Metastases - the PRESENT Cohort

Bone metastases are frequent distant manifestations of cancer, with pain as a common and devastating consequence. The primary treatment for painful bone metastases, external beam radiation therapy, is moderately effective: about 60% of patients who undergo conventional radiotherapy experience (partial) pain relief. Several factors associated with treatment failure have been identified, but no attempts have been made to collapse these factors into a clinically useful prediction tool to predict treatment response. In addition, to aid in therapy selection based on expected survival time, development of survival models is essential. Finally, we need innovative treatments as alternatives or additive to standard treatment options to improve quality of life (QoL). For these reasons, we set up the PRESENT cohort study, recruiting patients at the departments of radiation oncology and orthopedic surgery.

We aim to provide detailed information about clinical data, create an infrastructure for efficient, fast and pragmatic evaluation and implementation of innovative interventions, as well as development of accurate new prediction tools.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Medical Center Utrecht

Utrecht, 3508 GA, Netherlands

Location status: Recruiting

Location contact

Helena M. Verkooijen, MD PhD

CONTACT

[email protected]

Roxanne Gal, PhD

CONTACT

[email protected]

About this study

The PRESENT cohort is set up according to the 'cohort multiple Randomised Controlled Trial' design. The basis of this design is a prospective cohort of patients with bone metastases, receiving care as usual, who give informed consent for cohort participation. At the UMC Utrecht, patients are furthermore asked for informed consent to be randomized in future RCTs conducted within the cohort. Patients are informed that they will be offered the experimental intervention if they are randomly selected. They are also informed that they otherwise might serve as controls without being notified and that their data can be used in a trial context. For each patient in the cohort, clinical and patient-reported outcomes are captured at baseline and at regular intervals during follow-up. Within this cohort, multiple RCTs can be conducted. For this purpose, eligible patients who have provided the consent required for them to participate in an RCT within the cohort are identified. From this subcohort, a random selection of patients will be invited to undergo the experimental intervention. Eligible participants who were not randomly selected receive standard care, are not informed about the experimental intervention and serve as controls. Outcomes in this control group are compared with the outcomes of those who were offered the experimental intervention, in order to estimate the effect of the experimental intervention versus usual care. Within the cohort, the same process can be repeated for trials of other interventions.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histologic proof of malignancy;
  • Radiographic or histologic proof of metastatic bone disease;
  • Undergoing radiotherapy;
  • Age > 18 years;
  • Informed consent - at least - for use of routinely collected clinical data.

Exclusion criteria

  • Mentally incompetent patients;
  • Life expectancy < 1 week indicated by the treating physician.

Treatment and study plan

Primary outcomes

  1. Pain response

    Time frame: at 2, 4, 6, 8 weeks, 3 and 6 months, then every 6 months

Secondary outcomes

  1. Health-related Quality of Life

    Time frame: at 2, 4, 6, 8 weeks and 3 months

  2. Toxicity according to CTCAE version 4

    Time frame: up to 3 months

    Grade 3 and 4 side effects occurring during or up to 3 months after radiotherapy will be registered according to the Common Terminology Criteria for Adverse Events (CTCAE version 4). The following side effects will be registered: Nausea; Vomiting; Diarrhoea; Pain flare.

  3. Readmission

    Time frame: up to 3 years

    Reintervention (reirradiation, surgery, other); Development of neurological symptoms; Development of pathologic fracture

  4. Survival

    Time frame: up to 3 years

    Survival of participating patients will be recorded using the follow up questionnaires (returned by family members) or are derived from the Municipal Personal Records Database (in Dutch: Gemeentelijke Basisadministratie, GBA).

Study contacts

Contact information is provided by the study sponsor or research team.

Roxanne Gal, PhD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

UMC Utrecht

Other

Registry information

Acronym: PRESENT

Important dates

Study start
2013
Primary completion
2035
Study completion
2035
First posted
Feb 5, 2015
Registry last updated
Mar 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.